{"id":914193,"date":"2025-11-26T19:03:04","date_gmt":"2025-11-27T00:03:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/"},"modified":"2025-11-26T19:03:04","modified_gmt":"2025-11-27T00:03:04","slug":"hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/","title":{"rendered":"HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting"},"content":{"rendered":"
\n

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (\u201cHUTCHMED<\/a>\u201d) (Nasdaq\/AIM:\u200bHCM; HKEX:\u200b13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (\u201cESMO\u201d) Asia Congress 2025, taking place on December 5-7, 2025 in Singapore, and the American Society of Hematology (\u201cASH\u201d) Annual Meeting taking place on December 6-9, 2025 in Orlando, USA.<\/p>\n

Results from a first-in-human study of the anti-CD47 monoclonal antibody HMPL-A83 in advanced solid tumors, as well as from the phase II part of the FRUSICA-2 registration study of the fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma, will be presented at the ESMO Asia Congress 2025. Results from the phase II part of the phase II\/III study of surufatinib in combination with camrelizumab and chemotherapy as a first-line treatment for metastatic pancreatic cancer will also be reported. Details of the presentations are as follows:<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n Abstract title<\/strong>\n <\/td>\n\n Presenter<\/strong>
\n \/<\/strong>
\n Lead author<\/strong>\n <\/td>\n		\n Presentation details<\/strong>\n <\/td>\n<\/tr>\n
\n ESMO Asia Congress 2025 – <\/strong>
\n SPONSORED STUDIES<\/strong>\n <\/td>\n		\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n A first-in-human (FIH), dose escalation study of HMPL-A83 (A83), an anti-CD47 monoclonal antibody (mAb) in patients (pts) with advanced solid tumors<\/strong>
\n \n <\/td>\n		Ye Guo
(Shanghai, China)<\/td>\n		162MO | Mini Oral session: Developmental therapeutics and precision medicine
Sunday, December 7, 2025
11:40 – 11:45 SGT
Hall 407<\/td>\n<\/tr>\n
\n Fruquintinib monotherapy as second-line (2L) treatment in locally advanced or metastatic renal cell carcinoma (RCC): results from phase 2 part of FRUSICA-2<\/strong>\n <\/td>\nShanshan Wang\u00a0
(Shanghai, China)<\/td>\n		540O\u00a0| Proffered Paper session: Genitourinary tumours
Friday, December 5, 2025
14:55 – 15:05 SGT
Hall 402<\/td>\n<\/tr>\n
\n Surufatinib\u00a0(S) in combination with camrelizumab (C), nab-paclitaxel and gemcitabine (AG) as the first-line treatment in metastatic pancreatic cancer: results from phase 2 part of a randomized, open-label, active-controlled, phase 2\/3 study<\/strong>\n <\/td>\nShukui Qin\u00a0
(Nanjing, China)<\/td>\n		375P | Poster Display: Gastrointestinal tumours, non\u2011colorectal<\/td>\n<\/tr>\n
\n Osimertinib (osi) + savolitinib (savo) in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) with MET overexpression and\/or amplification (OverExp\/Amp) following progressive disease (PD) on osi: SAVANNAH Asian subset<\/strong>\n <\/td>\nSe-Hoon Lee\u00a0
(Seoul, Korea)<\/td>\n		982P | Poster Display:
Thoracic tumours, metastatic<\/td>\n<\/tr>\n
\n Patient-relevant Outcomes (PROs) from SACHI: a Phase 3 Trial of Savolitinib (Savo) plus Osimertinib (Osi) versus Chemotherapy (Chemo) in EGFR-mutant (EGFRm) and MET-amplified (METamp) Advanced NSCLC after Progression on EGFR-TKIs<\/strong>\n <\/td>\nYongfeng Yu\u00a0
(Shanghai, China)<\/td>\n		984P | Poster Display:
Thoracic tumours, metastatic<\/td>\n<\/tr>\n
\n Analysis of MET Amplification (METamp) with FISH and NGS Method in SACHI Trial<\/strong>\n <\/td>\nLonghua Sun\u00a0
(Nanchang, China)<\/td>\n		988P\u00a0| Poster Display:
Thoracic tumours, metastatic<\/td>\n<\/tr>\n
\n Progression pattern in patients (pts) with EGFR-mutant (EGFRm), MET-amplified (METamp) advanced NSCLC treated with savolitinib (savo) plus osimertinib (osi)<\/strong>\n <\/td>\nHaiyan Yang\u00a0
(Changsha, China)<\/td>\n		1002P | Poster Display:
Thoracic tumours, metastatic<\/td>\n<\/tr>\n
\n MET testing and treatment (tx) sequencing after progression of disease<\/strong>
\n (PD) on first-line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and\/or amplification (OverExp\/Amp): Final analysis of a global real-world (rw) study<\/strong>\n <\/td>\n		Julia Rotow\u00a0
(Boston, US)<\/td>\n		1005P | Poster Display:
Thoracic tumours, metastatic<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n ESMO Asia Congress 2025 –\u00a0<\/strong>
\n INVESTIGATOR-INITIATED STUDIES<\/strong>\n <\/td>\n		\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Fruquintinib Combined with TAS-102 with or without SBRT as Third- or Later-Line Treatment in Metastatic Colorectal Cancer: Preliminary Results from a Prospective Phase II Trial<\/strong>\n <\/td>\nChen Zhang\/ Yi Wang
(Ningbo, China)<\/td>\n		205P | Poster Display: Gastrointestinal tumours, colorectal<\/td>\n<\/tr>\n
\n Efficacy and safety of fruquintinib combined with PD-1 inhibitor and chidamide in MSS mCRC: a comparison with real-world bevacizumab plus anti-pd-1 and chidamide arm<\/strong>\n <\/td>\nGuanghai Dai\/ Miaomiao Gou
(Beijing, China)<\/td>\n		245eP | Poster Display: Gastrointestinal tumours, colorectal<\/td>\n<\/tr>\n
\n The Efficacy and Safety of Fruquintinib (F) Plus FOLFIRI as Second-line \u00a0(2L) Treatment in Bevacizumab (Bev)-pretreated RAS-mutated (RAS\u2011m) Metastatic Colorectal Cancer (mCRC)<\/strong>\n <\/td>\nZhenyang Liu\/ Xiaolin Yang
(Changsha, China)<\/td>\n		250eP | Poster Display: Gastrointestinal tumours, colorectal<\/td>\n<\/tr>\n
\n Real-world Observational Study of Fruquintinib in Combination with Irinotecan and Capecitabine as Second-line Treatment in Patients with Advanced Colorectal Cancer<\/strong>\n <\/td>\nXiujuan Qu\/ Lin Xu
(Shenyang, China)<\/td>\n		255eP | Poster Display: Gastrointestinal tumours, colorectal<\/td>\n<\/tr>\n
\n Matching-Adjusted Indirect Comparison of\u00a0Surufatinib\u00a0versus High-Dose Octreotide LAR in Advanced Extrapancreatic Neuroendocrine Tumors<\/strong>\n <\/td>\nJianming Xu\u00a0
(Beijing, China)<\/td>\n		214P | Poster Display: Gastrointestinal tumours, colorectal<\/td>\n<\/tr>\n
\n Efficacy and safety of\u00a0surufatinib\u00a0in combination with CAPTEM as conversion therapy in patients with unresectable pancreatic neuroendocrine tumors (pNETs): Data updates from a prospective, open-label study<\/strong>\n <\/td>\nXubao Liu\/ Ziyao Wang\u00a0
(Chengdu, China)<\/td>\n		400P | Poster Display: Gastrointestinal tumours, non\u2011colorectal<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

Final analysis of long-term results of sovleplenib\u2019s\u00a0ESLIM-01 China Phase III study in in adult patients with chronic primary immune thrombocytopenia will be presented at the 2025 ASH Annual Meeting. Details of the presentation is as follows:<\/p>\n\n\n\n\n\n
\n Abstract title<\/strong>\n <\/td>\n\n Presenter<\/strong>
\n \/<\/strong>
\n Lead author<\/strong>\n <\/td>\n		\n Presentation details<\/strong>\n <\/td>\n<\/tr>\n
\n 2025 ASH Annual Meeting – <\/strong>
\n SPONSORED STUDIES<\/strong>\n <\/td>\n		\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia<\/strong>
\n \n <\/td>\n		Renchi Yang
(Tianjin, China)<\/td>\n		843 | Oral Abstract Session
Monday, December 8, 2025
15:15 – 15:30 EST
Room OCCC – W304EFGH<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n About Fruquintinib<\/strong>\n <\/p>\n

Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors (\u201cVEGFR\u201d) -1, \u20112 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE\u00ae<\/sup>. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA\u00ae<\/sup>.<\/p>\n

\n About HMPL-A83 <\/strong>\n <\/p>\n

HMPL-A83 is an investigational IgG4-type humanized anti-CD47 monoclonal antibody that exhibits high affinity for CD47. HMPL-A83 blocks CD47 binding to Signal regulatory protein (SIRP) \u03b1 and disrupts the \u201cdo not eat me\u201d signal that cancer cells use to shield themselves from the immune system. HUTCHMED currently retains all rights to HMPL-A83 worldwide.<\/p>\n

\n About Savolitinib <\/strong>\n <\/p>\n

Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib\u00a0is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS\u00ae<\/sup>.<\/p>\n

\n About Surufatinib<\/strong>\n <\/p>\n

Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body\u2019s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA\u00ae<\/sup>. HUTCHMED currently retains all rights to surufatinib worldwide.<\/p>\n

\n About Sovleplenib<\/strong>\n <\/p>\n

Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting the spleen tyrosine kinase, also known as Syk. Syk is a major component in B-cell receptor and Fc receptor signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders. HUTCHMED currently retains all rights to sovleplenib worldwide.<\/p>\n

\n About HUTCHMED<\/strong>\n <\/p>\n

HUTCHMED (Nasdaq\/AIM:\u200bHCM; HKEX:\u200b13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch\u2011med.com<\/a> or follow us on LinkedIn<\/a>.<\/p>\n

\n
\n Forward-Looking Statements <\/em>
\n <\/strong>\n <\/p>\n

\n This press release contains forward-looking statements within the meaning of the \u201csafe harbor\u201d provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED\u2019s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib, the further clinical development for fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib, its expectations as to whether any studies on fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study\u2019s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, HMPL-A83, surufatinib, savolitinib and sovleplenib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products\u00a0such as camrelizumab and osimertinib as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED\u2019s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.<\/em>\n <\/p>\n

\n
\n Medical Information<\/em>
\n <\/strong>\n <\/p>\n

\n This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. <\/em>\n <\/p>\n

\n CONTACTS<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n Investor Enquiries<\/strong>\n <\/td>\n+852\u00a02121\u00a08200 \/ ir@hutch-med.com<\/a><\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Media Enquiries<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
FTI\u00a0Consulting \u2013<\/td>\n+44\u00a020\u00a03727\u00a01030\u00a0\/ HUTCHMED@fticonsulting.com<\/a><\/td>\n<\/tr>\n
Ben Atwell \/ Tim Stamper<\/td>\n+44 7771 913 902 (Mobile) \/ +44 7421 898 348 (Mobile)<\/td>\n<\/tr>\n
Brunswick \u2013 Zhou Yi<\/td>\n+852\u00a09783\u00a06894\u00a0(Mobile)\u00a0\/ HUTCHMED@brunswickgroup.com<\/a><\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Panmure Liberum<\/strong>\n <\/td>\n\n Nominated Advisor and Joint Broker<\/em>\n <\/td>\n<\/tr>\n
Atholl Tweedie\u00a0\/ Emma Earl\u00a0\/ Rupert Dearden<\/td>\n+44\u00a020\u00a07886\u00a02500<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Cavendish<\/strong>\n <\/td>\n\n Joint Broker<\/em>\n <\/td>\n<\/tr>\n
Geoff Nash\u00a0\/ Nigel Birks<\/td>\n+44\u00a020\u00a07220\u00a00500<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Deutsche Numis<\/strong>\n <\/td>\n\n Joint Broker<\/em>\n <\/td>\n<\/tr>\n
Freddie Barnfield \/ Jeffrey Wong \/ Duncan Monteith<\/td>\n+44 20 7260 1000<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (\u201cHUTCHMED\u201d) (Nasdaq\/AIM:\u200bHCM; HKEX:\u200b13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (\u201cESMO\u201d) Asia Congress 2025, taking place on December 5-7, 2025 in Singapore, and the American Society of Hematology (\u201cASH\u201d) Annual Meeting taking place on December 6-9, 2025 in Orlando, USA. Results from a first-in-human study of the anti-CD47 monoclonal antibody HMPL-A83 in advanced solid tumors, as well as from the phase II part of the FRUSICA-2 registration study of the fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell … <\/p>\n

Continue reading “HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-914193","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (\u201cHUTCHMED\u201d) (Nasdaq\/AIM:\u200bHCM; HKEX:\u200b13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (\u201cESMO\u201d) Asia Congress 2025, taking place on December 5-7, 2025 in Singapore, and the American Society of Hematology (\u201cASH\u201d) Annual Meeting taking place on December 6-9, 2025 in Orlando, USA. Results from a first-in-human study of the anti-CD47 monoclonal antibody HMPL-A83 in advanced solid tumors, as well as from the phase II part of the FRUSICA-2 registration study of the fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell … Continue reading "HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-27T00:03:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5Mjc5NiM3Mjk0MTgyIzIwOTY3MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting\",\"datePublished\":\"2025-11-27T00:03:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\\\/\"},\"wordCount\":1629,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5Mjc5NiM3Mjk0MTgyIzIwOTY3MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\\\/\",\"name\":\"HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5Mjc5NiM3Mjk0MTgyIzIwOTY3MTU=\",\"datePublished\":\"2025-11-27T00:03:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5Mjc5NiM3Mjk0MTgyIzIwOTY3MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5Mjc5NiM3Mjk0MTgyIzIwOTY3MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting - Market Newsdesk","og_description":"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (\u201cHUTCHMED\u201d) (Nasdaq\/AIM:\u200bHCM; HKEX:\u200b13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (\u201cESMO\u201d) Asia Congress 2025, taking place on December 5-7, 2025 in Singapore, and the American Society of Hematology (\u201cASH\u201d) Annual Meeting taking place on December 6-9, 2025 in Orlando, USA. Results from a first-in-human study of the anti-CD47 monoclonal antibody HMPL-A83 in advanced solid tumors, as well as from the phase II part of the FRUSICA-2 registration study of the fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell … Continue reading \"HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-27T00:03:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5Mjc5NiM3Mjk0MTgyIzIwOTY3MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting","datePublished":"2025-11-27T00:03:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/"},"wordCount":1629,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5Mjc5NiM3Mjk0MTgyIzIwOTY3MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/","name":"HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5Mjc5NiM3Mjk0MTgyIzIwOTY3MTU=","datePublished":"2025-11-27T00:03:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5Mjc5NiM3Mjk0MTgyIzIwOTY3MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5Mjc5NiM3Mjk0MTgyIzIwOTY3MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-2025-esmo-asia-congress-and-the-2025-ash-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/914193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=914193"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/914193\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=914193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=914193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=914193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}